May 17, 2024 12:00 PM EDT
R&D
FDA+

FDA re­jects liv­er can­cer drug com­bo, shares of Ko­re­an biotech tank

Kyle LaHucik

Senior Reporter

Ko­re­an biotech HLB and its Chi­na-based part­ner Jiang­su Hen­grui Phar­ma­ceu­ti­cals said Fri­day that the FDA re­ject­ed their drug com­bi­na­tion for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times